Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

Abstract Purpose of Review Osteonecrosis of the jaw (ONJ) is a rare and severe necrotic
bone disease reflecting a compromise in the body's osseous healing mechanisms and …

Since the initial description of medication‐related osteonecrosis of the jaw (MRONJ) almost
two decades ago, the potential pathophysiology and risk factors have been elaborated on in …

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug
effect. There are multiple hypotheses to explain the development of MRONJ. Reduced bone …

This work investigated whether the anti-resorptive drugs (ARDs) zoledronic acid (Zol) and
denosumab (Dmab) affect differently the levels of circulating immune cell subsets, possibly …

The pathogenesis of medication-related osteonecrosis of the jaw (MRONJ) is multifactorial
and there is a substantial consensus on the role of antiresorptive drugs (ARDs), including …

Medication-related osteonecrosis of the jaw (MRONJ), a severe side effect caused by
antiresorptive antiangiogenic medication, particularly bisphosphonates (BPs), has become a …

Various conditions, including bacterial infection, can promote osteonecrosis. For example,
following invasive dental therapy with anti-bone resorptive agents, some patients develop …

Treatment with cumulative dosages of zoledronic acid (ZA) in elderly patients is a risk factor
for the development of medication-related osteonecrosis of the jaws (MRONJ), mainly …

Although periprosthetic osteolysis induced by wear debris particles is significantly elevated
in senior (65+ years old) patients, most of the published pre-clinical studies were performed …